August 2012

Watson Pharmaceuticals has launched a generic levalbuterol inhalation solution, an authorized version of Sunovion’s Xopenex for the treatment of asthma. Shipments will begin immediately. The company cites IMS Health data saying that sales of Xopenex… Read more . . .

According to a newspaper report, Novartis has confirmed that it will retain its respiratory disease research center in Horsham, UK, with 440 employees. The company will sell a portion of the site and plans to… Read more . . .

GE Capital Healthcare Financial Services has announced today that it is providing $7.5 million in financing to Trimel Pharmaceuticals for Phase 2 and 3 clinical development of several OINDPs. Trimel’s pipeline includes asthma and allergic… Read more . . .

Israeli biopharmaceutical company Kamada will receive milestone payments of $60 million as part of a 12-year distribution agreement with Chiesi Farmaceutici for Kamada’s inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency (AATD-IH). Chiesi… Read more . . .

According to Insmed, the US Patent and Trademark Office has issued the company a second composition of matter patent for Arikace liposomal amikacin for inhalation, US Patent No. 8,226,975. Insmed is developing the product for… Read more . . .

Aptar Pharma has announced that the Zetonna nasal aerosol device recently launched in the US includes a customized Aptar Landmark dose indicator, the result of a six-year collaboration with Sunovion. Zetonna is delivered by a… Read more . . .